TNFRSF17 and neoplasm: Due to its high expression and antigen stability, FcRH5 has been increasingly included into poly- and bi-specific CAR platforms (for instance, FcRH5+BCMA and FcRH5+GPRC5D), which is particularly promising for combating antigen escape in the case of tumor heterogeneity [39,134].